Available IPD datapackage for study 'A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01)'

Name: Available IPD datapackage for study 'A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01)'
Creator: Vivli
Published: 2025-05-01 01:01:28
License: 暂无描述

DataCite Commons2025-05-01 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/dataPackages/PR00007153_0

下载链接

链接失效反馈

官方服务：

资源简介：

Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.

提供机构：

Vivli

创建时间：

2022-06-09